The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
Tumor material, ascites (if possible) and blood samples for immune monitoring will be collected from patients with primary and recurrent EOC undergoing surgery, chemotherapy and/or immunotherapy.
Study Type
OBSERVATIONAL
Enrollment
300
Observational study, no intervention
Leiden University Medical Center
Leiden, Netherlands
RECRUITINGAssociation between the mMDSC/DC ratio in PBMCs in patients with recurrent EOC before the start of treatment and OS
Time frame: 5 years
Association between the mMDSC/DC ratio in PBMCs in patients with recurrent EOC before the start of treatment and PFS
Time frame: 5 years
Association between the mMDSC/DC ratio in PBMCs in patients with primary EOC before the start of treatment and OS
Time frame: 5 years
Association between the mMDSC/DC ratio in PBMCs in patients with primary EOC before the start of treatment and PFS
Time frame: 5 years
Interaction between the mMDSC/DC ratio in PBMCs and EOC groups on OS
Time frame: 5 years
Interaction between the mMDSC/DC ratio in PBMCs and EOC groups on PFS
Time frame: 5 years
Association between mMDSC/DC ratio in PBMCs measured at different time points in patients with primary EOC and OS
Time frame: 5 years
Association between mMDSC/DC ratio in PBMCs measured at different time points in patients with recurrent EOC and OS
Time frame: 5 years
Association between mMDSC/DC ratio in PBMCs measured at different time points in patients with primary EOC and PFS
Time frame: 5 years
Association between mMDSC/DC ratio in PBMCs measured at different time points in patients with recurrent EOC and PFS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 5 years
Composition/counts of myeloid cells in PBMCs in patients with primary EOC before and during treatment and the association with OS
Time frame: 5 years
Function of myeloid cells (assessed by functional suppression assay) in PBMCs in patients with primary EOC before and during treatment and the association with OS
Time frame: 5 years
Composition/counts of myeloid cells in PBMCs in patients with recurrent EOC before and during treatment and the association with OS
Time frame: 5 years
Function of myeloid cells (assessed by functional suppression assay) in PBMCs in patients with recurrent EOC before and during treatment and the association with OS
Time frame: 5 years
Composition/counts of myeloid cells in PBMCs in patients with primary EOC before and during treatment and the association with PFS
Time frame: 5 years
Function of myeloid cells (assessed by functional suppression assay) in PBMCs in patients with primary EOC before and during treatment and the association with PFS
Time frame: 5 years
Composition/counts of myeloid cells in PBMCs in patients with recurrent EOC before and during treatment and the association with PFS
Time frame: 5 years
Function of myeloid cells (assessed by functional suppression assay) in PBMCs in patients with recurrent EOC before and during treatment and the association with PFS
Time frame: 5 years
Influence of the mMDSC/DC ratio and separate immune cell populations on the tumor specific and general immune response (assessed by mixed lymphocyte reaction, functional suppression assay and lymphocyte stimulation test)
Time frame: 5 years
Determined, optimized and validated optimal cut-off point for the macrophage/DC ratio and the mMDSC/DC ratio in PBMCs in patients with primary EOC for the different chemotherapeutic and immunotherapeutic treatment modalities
Time frame: 5 years
Determined, optimized and validated optimal cut-off point for the macrophage/DC ratio and the mMDSC/DC ratio in PBMCs in patients with recurrent EOC for the different chemotherapeutic and immunotherapeutic treatment modalities
Time frame: 5 years
Immune contexture of primary tumors by determination of the intratumoral immune subset numbers in fresh and archived tumor material and the association with OS
Time frame: 5 years
Immune contexture of recurrent tumors by determination of the intratumoral immune subset numbers in fresh and archived tumor material and the association with OS
Time frame: 5 years
Immune contexture of primary tumors by determination of the intratumoral immune subset numbers in fresh and archived tumor material and the association with PFS
Time frame: 5 years
Immune contexture of recurrent tumors by determination of the intratumoral immune subset numbers in fresh and archived tumor material and the association with PFS
Time frame: 5 years
Immune contexture of ascites by determination of the immune subset numbers in ascites fluid of patients with primary EOC and the association with OS
Time frame: 5 years
Immune contexture of ascites by determination of the immune subset numbers in ascites fluid of patients with recurrent EOC and the association with OS
Time frame: 5 years
Immune contexture of ascites by determination of the immune subset numbers in ascites fluid of patients with primary EOC and the association with PFS
Time frame: 5 years
Immune contexture of ascites by determination of the immune subset numbers in ascites fluid of patients with recurrent EOC and the association with PFS
Time frame: 5 years